Our indicative theme of Gene Editing stocks remains down by about 11% year-to-date, meaningfully underperforming the S&P 500 which is up by about 19% over the same period. In fact, if we exclude a single stock Intellia Therapeutics, which is up by about 2.4x year-to-date, the other stocks are down..
Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?
Forbes - 19 Oct 2021 17:15
Our indicative theme of Gene Editing stocks remains down by about 11% year-to-date, meaningfully underperforming the S&P 500 which is up by about 19% over the same period. In fact, if we exclude a single stock Intellia Therapeutics, which is up by about 2.4x year-to-date, the other stocks are down..
Share this Article
Recommended